Ronald Renaud

Ronald C.
Renaud is President, Chief Executive Officer & Director at Kailera Therapeutics, Inc. since 2024.
He is Chairman at Upstream Bio, Inc. since 2021.
He serves as Director at Jnana Therapeutics, Inc., Trustee at St. Anselm College, Member of the Overseers Board at Newton-Wellesley Hospital Corp., and Senior Advisor at Bain Capital Life Sciences LP since 2023.
Former positions include President, CEO, CFO & Director at Idenix Pharmaceuticals LLC from 2010 to 2014; Chairman & Chief Executive Officer at Translate Bio, Inc. in 2021; President, Chief Executive Officer & Director at Cerevel Therapeutics Holdings, Inc. from 2023 to 2024; Chairman at Ikena Oncology, Inc. from 2018 to 2022; Managing Director at Bear, Stearns & Co., Inc.; Managing Director at Charles Schwab & Co., Inc. from 2001 to 2004; Independent Class Director at PTC Therapeutics, Inc. from 2015 to 2017; Independent Director at Akebia Therapeutics, Inc. from 2014 to 2018; Board of Directors at American Liver Foundation of Northern California from 2012 to 2014; Managing Director at Soundview Capital Management Corp.
from 2001 to 2004; Independent Director at Vertero Therapeutics, Inc. starting 2017; Independent Director at Chimerix, Inc. from 2014 to 2021; Chief Financial Officer, Treasurer & Senior VP at Keryx Biopharmaceuticals, Inc. from 2006 to 2007; Analyst at JPMorgan Securities LLC in 2006; Research Analyst at Schwab SoundView Capital Markets from 2003 to 2004; Chairperson of the Board at Atara Biotherapeutics, Inc. from 2020 to 2022; Partner at Bain Capital Holdings LP from 2022 to 2023; and Advisor at Atlas Venture Advisors, Inc.Education includes an undergraduate degree from St. Anselm College conferred in 1990 and an MBA from USC Marshall School of Business conferred in 1999.